Canaccord Genuity Rates Cybin D Helus Pharma (HELP) buy
Canaccord Genuity maintains its buy rating on HELP, setting a $42 price target, a 546.14% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Canaccord Genuity rated Cybin D/B Helus Pharma ($HELP) "buy" with a $42 price target on July 1, 2026.
Since the rating, $HELP is down 0.8% after 1 week, up 24.5% after 1 month and up 68.0% to date (from the $6.28 close on Jul 1, 2026).
HELP
Cybin D/B Helus Pharma
Key Points
- Canaccord Genuity reiterated its buy rating on HELP, setting a price target of $42 as of July 1, 2026.
- Canaccord Genuity's $42 price target implies 546.14% upside from Cybin D/B Helus Pharma's ($HELP) current $6.50 share price.
- Shares of HELP traded near $6.94 on Wednesday, reflecting investor interest following recent analyst updates.
- Other institutions like Venrock Adviser and Millennium Management adjusted their holdings in HELP.
Get $HELP trade alerts by text
We text you when insiders, Congress or big funds trade $HELP. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cybin D/B Helus Pharma alert may contain errors. Disclosures
On July 1, 2026, Canaccord Genuity reiterated its buy rating on HELP with a price target of $42. Analyst Sumant Kulkarni maintained this optimistic outlook, suggesting confidence in the company's potential.
Canaccord Genuity vs. the S&P 500
Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in HELP
Several institutional investors have adjusted their positions in HELP. Venrock Adviser, LLC increased its holdings by 11,404 shares, bringing its total to 3,851,654 shares valued at approximately $18.49 million. Millennium Management LLC made a significant move, adding 1,387,292 shares, resulting in a total of 2,415,841 shares worth about $11.60 million, marking a 134.9% increase. On the other hand, Orbimed Advisors LLC trimmed its position by 7,657 shares, now holding 3,832,843 shares valued at $18.40 million. Acorn Capital Advisors, LLC and Rosalind Advisors, Inc. also reduced their holdings by 32,757 and 125,726 shares, respectively.
Cybin D/B Helus Pharma Stock Down 47.5%
Shares of HELP traded near $6.94 on Wednesday. The company has seen various institutional activities, reflecting diverse investor strategies. While specific market cap and P/E ratio details are not available, the stock has been receiving attention from analysts, as indicated by the reiterated buy rating from Canaccord Genuity.
$HELP price target
Cybin D/B Helus Pharma daily closes and this analyst's $42 target. Not advice.
Analysts Set New Price Targets
On July 1, 2026, Canaccord Genuity maintained its buy rating on HELP with a $42 price target. Earlier, on April 13, 2026, TD Cowen initiated coverage with a buy rating and an $8 target. HC Wainwright & Co. also maintained a buy rating with a $95 target on March 2, 2026. The consensus among analysts suggests a positive outlook for HELP, with a general buy recommendation.
About HELP
HELP is a company involved in [industry/sector] activities. While detailed information about its operations and leadership is not provided, the company is actively followed by investors and analysts, indicating its relevance in the market.
Bottom Line
Canaccord Genuity's reiterated buy rating and $42 price target for HELP underscore a positive outlook from analysts. Institutional investors are actively adjusting their positions, reflecting varied strategies and confidence levels. As always, these insights are based on backward-looking data and past filings, which may not represent the current situation.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $HELP (Jul 1, 2026). Written by software, not financial advice. How we make alerts